Maxwell Biosciences Ask Me Anything with CEO J Scotch Mcclure at EARD 2023

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=HuH8jvNpASM

J. Scotch Mcclure, CEO of Maxwell Biosciences at the Longevity+DeSci Summit NYC (EARD 2023). • SUMMARY • ▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀ • Mr. McClure is an experienced engineer, CEO, and corporate board director with a background in military intelligence and commercial technology. He is an inventor with patents in antiviral applications and human gene expression technology, and has led engineering and scientific research teams. His accomplishments include designing the world's first dual-core laptop and pioneering work in plasma proteomics and biomimetic drug design. With a diverse educational background including a B.S. in Management from the USAF Academy and an MBA from the University of Massachusetts, Mr. McClure served in the United States Air Force for nearly a decade in classified intelligence project management roles. • Maxwell Biosciences is a preclinical stage drug platform company partnering with large pharma companies to develop an entirely new class of patented low molecular weight drug candidates that destroy SARS-CoV-2, the COVID virus, as well as other viruses and infectious pathogens (including fungal and bacterial pathogens). Maxwell's first-in-class CLAROMER™ brand drug discovery platform mimics natural human immune system antimicrobial and antiviral peptides. Maxwell Biosciences has benefitted from over $35M of non-dilutive grants and awards from governments around the world to validate their science and technology, including studies by US Govt-funded labs confirming that Maxwell's lead drug candidate has direct virucidal action against Herpes virus (HSV-1) and SARS-CoV-2, the COVID virus. Additionally, live mouse safety data at Texas A M show Maxwell's drugs benefit from a tissue-safe toxicology profiles, and live mouse studies from the Baylor College of Medicine show breakthrough fungicidal action with CLAROMER™ brand compounds against lethal fungal infections of the upper-respiratory tract. These findings support the expected safety and effectiveness of Maxwell's “multi-asset, multi-target” anti-infectives drug platform. Maxwell's drug platform is supported by a granted patent portfolio and is strongly positioned in the fight against emergent viral pandemics and a broad spectrum of evolving infectious pathogens. Maxwell is raising funds for advanced preclinical and human trials. • FOLLOW US • ▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀ • https://www.lifespan.io • / lifespanio • / lifespanio • / lifespan.io • HOW CAN YOU SUPPORT US? • ▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀ • Lifespan.io, a 501(c)(3) nonprofit organization. • ► Support us with monthly donations by becoming a Lifespan Hero: https://www.lifespan.io/support • ► Subscribe: https://www.youtube.com/user/Lifespan... • ► Learn more, and help us: https://www.lifespan.io • #longevity #EARD2023 #desci #decentralized #biotechnology #biology #healthscience #livelonger #agingbackwards #lifespan #healthspan #biotech #biotechnology #longevity #longevitylifestyle #stayhealthy #healthscience #rejuvenation

#############################

New on site